More about

Prostate Cancer

News
May 06, 2023
7 min watch
Save

Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume

Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume

Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.

News
May 01, 2023
2 min read
Save

Adding enzalutamide to ADT cuts risk for metastasis by 58% in prostate cancer subgroup

Adding enzalutamide to ADT cuts risk for metastasis by 58% in prostate cancer subgroup

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.

News
April 28, 2023
3 min read
Save

FDA committee favors restricting prostate cancer regimen to BRCA-positive subgroup

FDA committee favors restricting prostate cancer regimen to <i>BRCA</i>-positive subgroup

An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.

News
April 20, 2023
2 min read
Save

Are providers too cautious with prescribing testosterone therapy?

Are providers too cautious with prescribing testosterone therapy?

Providers are too cautious with testosterone therapy. The myth is that increasing testosterone level will cause prostate cancer. If you start with a myth, you have to disprove that myth with a trial that is probably too big to ever conduct and that nobody will ever fund. Although repeated studies have shown no risks with testosterone therapy, those small studies are never looked at.

News
April 11, 2023
2 min read
Save

New genetic risk factors for prostate cancer identified in men of African ancestry

New genetic risk factors for prostate cancer identified in men of African ancestry

A genome-wide association study of more than 80,000 men with prostate cancer identified nine new genetic risk factors for prostate cancer, including seven mainly or exclusively among men of African ancestry.

News
April 03, 2023
2 min read
Save

More men with prostate cancer opting for active surveillance

More men with prostate cancer opting for active surveillance

Use of active surveillance for low-risk and favorable intermediate-risk prostate cancer increased sharply in the United States during the past decade, according to data published in JAMA Internal Medicine.

News
March 20, 2023
3 min read
Save

Study highlights need to include more African men in prostate cancer genetic testing

Study highlights need to include more African men in prostate cancer genetic testing

Guidelines are urgently needed to ensure inclusion of men of African ancestry in genetic testing for advanced, early-onset and familial prostate cancers, according to research in Journal of the National Comprehensive Cancer Network.

News
March 17, 2023
1 min read
Save

Enzalutamide regimen prolongs metastasis-free survival in nonmetastatic prostate cancer

Enzalutamide regimen prolongs metastasis-free survival in nonmetastatic prostate cancer

A combination of enzalutamide and leuprolide significantly extended metastasis-free survival for men with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to a company press release.

News
March 17, 2023
2 min watch
Save

VIDEO: MMAI biomarker shows prognostic abilities in prostate cancer

VIDEO: MMAI biomarker shows prognostic abilities in prostate cancer

In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the MMAI trial presented at ASCO Genitourinary Cancers Symposium.

News
March 16, 2023
2 min read
Save

Polygenic risk score does not improve prediction of aggressive prostate cancer

Polygenic risk score does not improve prediction of aggressive prostate cancer

A prostate cancer polygenic risk score did not better predict the risk for aggressive disease compared with a clinical risk predictor and may not be clinically useful, according to study results published in JAMA Internal Medicine.

View more